Nabriva Therapeutics Announces Acceptance of the New Drug

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
301
Nabriva Therapeutics Announces Acceptance of the New Drug Application for Intravenous CONTEPO™ to Treat Complicated Urinary Tract Infections by FDA

DUBLIN, Ireland, Jan. 04, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted a priority review for CONTEPO™ (fosfomycin for injection) to treat complicated urinary tract infections (cUTIs), including acute pyelonephritis. The acceptance of the NDA indicates that the FDA has deemed the application sufficiently complete to allow a substantive review. The PDUFA (Prescription Drug User Fee Act) goal date for the completion of the FDA’s review of the CONTEPO NDA is June 30, 2019. In addition to priority review, CONTEPO has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the FDA for the treatment of several serious infections, including cUTI.

“The acceptance of the CONTEPO NDA marks another major milestone for Nabriva Therapeutics, demonstrating our commitment to bring novel anti-infective agents that address the urgent, unmet medical need in patients with serious infections,” said Dr. Jennifer Schranz, chief medical officer of Nabriva Therapeutics. “CONTEPO, if approved in the United States, represents a first-in-class intravenous antibiotic with broad spectrum activity against Gram-negative and Gram-positive organisms, including ESBL-producing Enterobacteriaceae and other contemporary multi-drug resistant (MDR) organisms.”

The NDA submission is utilizing the 505(b)(2) regulatory pathway and is supported by a robust data package, including a pivotal Phase 2/3 clinical trial (known as ZEUS™), which met its primary endpoint of statistical non-inferiority to piperacillin/tazobactam in patients with cUTI, including acute pyelonephritis.

In the NDA acceptance letter, the FDA stated that no filing or potential review issues were identified. In addition, the Agency stated that it has not referred CONTEPO to an advisory committee meeting at this time.

About cUTIs
Urinary tract infections (UTIs) are a significant health problem in both the community- and hospital-based treatment settings. It is estimated that 150 million UTIs occur yearly worldwide, accounting for $6 billion in health care expenditures, according to the American Urological Association. Patients who fail to respond to an initial course of antibiotics can go on to develop a cUTI, which occurs when the bacteria are embedded in the bladder wall where they can multiply more slowly and are much harder to address with antibiotics. In most cases, cUTIs occur following treatment for a normal UTI because antibiotics were given too late, for too short a period of time, at too low of a dose course or the wrong antibiotic was used and did not provide adequate spectrum of coverage. An estimated three million cases of cUTIs are treated in the hospital setting in the United States each year for Gram-negative infections. Enterobacteriaceae are the most common pathogens causing cUTIs and, currently, widespread antibiotic resistance limits the effective treatment options for cUTI. Ineffectively managed cUTI can lead to increased treatment failure rates, recurrence of infection, increased re-hospitalization, and increased morbidity and mortality.

About CONTEPO™
CONTEPO™ (fosfomycin for injection, previously referred to as ZTI-01 and ZOLYD) is a novel, potentially first-in-class in the United States, intravenous investigational antibiotic with a broad spectrum of Gram-negative and Gram-positive activity, including activity against most contemporary multi-drug resistant (MDR) strains such as ESBL-producing Enterobacteriaceae. Intravenous (I.V.) fosfomycin has been approved for a number of indications and utilized for over 45 years in Europe to treat a variety of infections, including cUTIs and other serious bacterial infections. CONTEPO utilizes a new dosing approach, originally developed by Zavante (which Nabriva Therapeutics acquired), to optimize its pharmacokinetics and pharmacodynamics. Nabriva Therapeutics believes these attributes, along with the positive clinical experience worldwide, support CONTEPO as a first-line treatment for cUTIs, including acute pyelonephritis, suspected to be caused by MDR pathogens. At least 20 percent of cUTIs are caused by MDR bacteria and limited treatment options are available in the U.S. In addition, non-clinical data have shown that CONTEPO acts in combination with certain other antibiotics to improve bacterial killing.

About Nabriva Therapeutics plc
Nabriva Therapeutics is a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics has two product candidates that are in late stage development: lefamulin, potentially the first systemic pleuromutilin antibiotic for CABP and CONTEPO (fosfomycin for injection), a potential first-in-class epoxide antibiotic in the United States for complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP). For more information, please visit https://www.nabriva.com.

Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Nabriva Therapeutics, including but not limited to statements about the development of Nabriva Therapeutics’ product candidates, such as the future development or commercialization of lefamulin and CONTEPO, conduct and timelines of clinical trials, the clinical utility of lefamulin for CABP and of CONTEPO for cUTI, plans for and timing of the review of regulatory filings, efforts to bring lefamulin and CONTEPO to market, the market opportunity for and the potential market acceptance of lefamulin for CABP and CONTEPO for cUTI, the development of lefamulin and CONTEPO for additional indications, the development of additional formulations of lefamulin and CONTEPO, plans to pursue research and development of other product candidates, the sufficiency of Nabriva Therapeutics’ existing cash resources and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including:  the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, Nabriva Therapeutics’ ability to realize the anticipated benefits, synergies and growth prospects of its acquisition of Zavante Therapeutics, the uncertainties inherent in the initiation and conduct of clinical trials, availability and timing of data from clinical trials, whether results of early clinical trials or studies in different disease indications will be indicative of the results of ongoing or future trials, whether results of ZEUS will be indicative of results for any ongoing or future clinical trials and studies of CONTEPO, uncertainties associated with regulatory review of clinical trials and applications for marketing approvals, the availability or commercial potential of product candidates including lefamulin for use as a first-line empiric monotherapy for the treatment of CABP and CONTEPO for the treatment of cUTI, the ability to retain and hire key personnel, the sufficiency of cash resources and need for additional financing and such other important factors as are set forth in Nabriva Therapeutics’ annual and quarterly reports and other filings on file with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Nabriva Therapeutics’ views as of the date of this press release. Nabriva Therapeutics anticipates that subsequent events and developments will cause its views to change. However, while Nabriva Therapeutics may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Nabriva Therapeutics’ views as of any date subsequent to the date of this press release.

CONTACTS:

FOR INVESTORS
Dave Garrett
Nabriva Therapeutics plc
david.garrett@nabriva.com
610-816-6657

For Media
Mike Beyer
Sam Brown Inc.
mikebeyer@sambrown.com
312-961-2502

Scroll down for more posts ▼

Top 10 Most Recent News Articles

GreenTree Faces Softer Rooms, Debt and NYSE Deadline

Updated Category News Views 34

A hotel operator can post positive earnings and still leave shareholders with a nasty headache, and GreenTree's third quarter is that kind of report. NYSE:GHG produced RMB243.0 million in revenue, down 22.2% from a year earlier, while net income slipped to RMB49.3 million from RMB59.0 million. This was not a one-line stumble. Room pricing, occupancy, franchise economics...

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 135

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
CCAPP Holiday Training Targets Seasonal Recovery Strain

Updated Category News Views 53

December cheer has a nasty habit of hiding the people barely holding themselves together. CCAPP’s upcoming virtual workshop, Hope for the Holidays: Understanding Depression, Stress & Resilience During the Holiday Season, takes that uncomfortable reality seriously rather than treating it like a seasonal footnote. For behavioral health workers supporting people in...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 73

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
Water Damage Coverage Has More Traps Than Homeowners Think

Updated Category News Views 36

A wet basement does not care one bit whether the water arrived dramatically or dripped in for months. That ugly distinction, though, can decide whether a homeowner has an insurance claim or a repair bill that lands with a thud. Kathy Thurmond-Edwards, an insurance expert in Memphis, Tennessee, lays out the dividing lines plainly: sudden pipe failures may be treated very...

Continue Reading
Cash Flow Discipline Is Where Business Growth Gets Real

Updated Category News Views 73

A full order book can still leave a company gasping at payroll. That is the unglamorous point behind the Nov. 20, 2026, HelloNation piece featuring Kimberly Furrh of Furrh & Associates PC in Lawton, Oklahoma. Owners love to talk about sales because sales are visible, flattering and easy to celebrate. Cash is less theatrical. It is also the thing that keeps the lights on...

Continue Reading
Dario's Personify Panel Puts Distribution Model in Focus

Updated Category News Views 246

A Partner Megaphone Is Not a Revenue Line Monday's virtual panel gives DarioHealth a useful stage, but investors should not confuse a conference microphone with a signed sales order. Erez Raphael is set to lead a November 23 discussion with Personify Health President Ed Liebowitz at the U.S. Bancorp | BTIG Tech-Enabled Healthcare Forum, running from noon to 12:50 p.m....

Continue Reading
HVAC’s $383.6 Billion Shift Is About More Than Units

Updated Category News Views 163

Server racks are turning cooling gear into a front-row industrial story, and that deserves more attention than the usual sleepy talk about replacement air conditioners. Frost & Sullivan projects the global HVAC equipment market will reach $383.6 billion by 2031, growing at a 7.0% compound annual rate from 2025. That is a sizable market, sure, but the more interesting...

Continue Reading
MTI Adds Aviation Veterans as Acorn Builds MRO Plan

Updated Category News Views 127

Two old hands entering a boardroom can matter more than another glossy growth slogan, especially in aircraft maintenance, where a delayed part can ground an airplane and turn a customer relationship sour in a hurry. MTI Aviation has added Tony DiSimone Sr. and Aviv Tzur to its board, a move announced November 20, 2026, after Acorn Capital Management took a majority...

Continue Reading
AlphaPoint's Approval Device Targets AI Attack Risk

Updated Category News Views 45

A Separate Screen May Be Worth More Than Another Patch AlphaPoint is taking a fairly old security instinct and aiming it at a very current headache: if the laptop is lying to the employee, do not let the laptop have the final say. Its newly introduced Approval Device is dedicated hardware with its own display, built to let authorized staff inspect and approve sensitive...

Continue Reading

Top 5 Most Recently Viewed Articles

Transforming Healthcare: ShiftMed Enhances Scheduling at UNC Health

Updated Category News Views 389

Introduction to ShiftMed Flex at UNC Health UNC Health is taking a significant step forward by implementing ShiftMed Flex, a transformative solution aimed at enhancing workforce efficiency throughout its network. This innovative AI-driven platform is designed to improve shift participation by better matching healthcare providers' schedules with available shifts,...

Continue Reading
Rivian's Q4 Financial Performance Sparks Investor Optimism

Updated Category News Views 168

Rivian's Strong Financial Performance Rivian Automotive stock has demonstrated significant resilience and growth recently. Investors are keen to understand the factors that are propelling RIVN stock upward. The latest quarterly earnings report has highlighted Rivian’s remarkable performance, which is robust evidence of the company's progress in the competitive electric...

Continue Reading
Purple Biotech's Innovative Advancements with CAPTN-3 Antibody Platform

Updated Category News Views 295

Exciting Developments in Cancer Treatment from Purple Biotech Purple Biotech, a clinical-stage company at the forefront of oncology, has made impressive strides in its novel tri-specific T cell and NK cell engager platform, known as CAPTN-3. This innovative approach demonstrates sustained tumor regression in an in-vivo model of triple-negative breast cancer and showcases...

Continue Reading
Raytron's Thermal Technology Enhances Robotaxi Safety in All Weather

Updated Category News Views 222

Raytron's Innovative Thermal Cameras for Autonomous Driving As advancements in technology reshape our transportation systems, one major player in the field is Raytron, a leader in infrared thermal imaging. A pressing challenge in the rollout of Level 4 (L4) robotaxis is ensuring safe operation in various climatic conditions, especially during extreme weather. With...

Continue Reading
Investors Urged to Join Centene Corporation Class Action Now

Updated Category News Views 116

Centene Corporation Faces Class Action Lawsuit Levi & Korsinsky, LLP has officially notified investors about a class action lawsuit targeting Centene Corporation. This lawsuit may affect shareholders who experienced losses due to alleged securities fraud. Centene Corporation, identified by its ticker CNC, is at the center of this legal action, which has drawn attention...

Continue Reading